Asked about recent changes to the fund's holdings, Berkowitz replied: "The big sales were Pfizer, defense related, Boeing, Northrop. At Fairholme we continue to sell that which is cheap to buy that which is cheaper. When we went into the drug industry and the defense business, it was defensive, we saw a storm coming. And we were right; these companies have maintained reasonably good earnings.
"But to some extent we were mistaken, because we found that when you are in a tremendous crisis, everything is correlated. And we were hoping that the companies would protect us more than they did. But we did all right.
"But now that we are through this financial earthquake, even though we expect maybe a few more aftershocks, we do expect a more normal environment. So we are shifting from defense to offense, and we need the cash, so we have moved on to some new positions. We are absolutely sure companies we have sold will do quite well. But I think we can do a bit better as our optimism about the future grows."
You can watch the video or read the transcript of the interview by clicking here.
